Clinical trial · Interventional
Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma
A Prospective Randomized Trial of Surgical Resection Versus Percutaneous Local Ablative Therapy for Hepatocellular Carcinoma Complicating Clinically Significant Portal Hypertension Within the Milan Criteria
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The aim of this study is to compare the operative complication and short-/long-term therapeutic effects of percutaneous local ablative therapy (PLAT) versus surgical resection(SR) on small hepatocellular carcinoma(HCC) patients with clinically significant portal hypertension(CSPH) so as to lend clinical and theoretical basis of the therapeutic schemes for the disease.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma With CSPH | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| PLAT | Procedure | — | UNRESOLVED |
| SR | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- SR
- interventionNames
- Procedure: SR
- type
- EXPERIMENTAL
- label
- PLAT
- interventionNames
- Procedure: PLAT
Primary outcomes (1)
- measure
- overall survival
- timeFrame
- 3 years
Secondary outcomes (1)
- measure
- local tumor progression
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. 18 Years \< ge ≤ 70 Y,KPS ≥ 70 2. A solitary HCC ≤ 5cm in diameter,or multiple HCC(≤3) ,each ≤3cm in diameter without evidence of radiologically definable vascular invasion or extrahepatic metastasis. allowing to both SR and PLAT 3. Child-Pugh class A or B,without history of encephalopathy,ascites refractory to diuretics,or variceal bleeding 4. NO previous treatment of HCC 5. Platelet count\>40,000/mm3；prothrombin time prolongation of no more than 3 seconds 6. Patients who can understand this trial and have signed information consent Exclusion Criteria: 1. metastatic liver cancer 2. Patients with apparent cardiac,pulmonary,cerebral and renal dysfunction,which may affect the treatment of HCC 3\) Patients with other diseases which may affect the treatment mentioned 4） Patients participating in other clinical trials 5） Patients with a medical history of other malignant tumors 6\) Pregnant and breast-feeding women
References
Publications (0)
Data not yet available